Cargando…

Population pharmacokinetics of bevacizumab in cancer patients with external validation

BACKGROUND: Bevacizumab is approved for various cancers. This analysis aimed to comprehensively evaluate bevacizumab pharmacokinetics and the influence of patient variables on bevacizumab pharmacokinetics. METHODS: Rich and sparse bevacizumab serum concentrations were collected from Phase I through...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Kelong, Peyret, Thomas, Marchand, Mathilde, Quartino, Angelica, Gosselin, Nathalie H., Girish, Sandhya, Allison, David E., Jin, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965493/ https://www.ncbi.nlm.nih.gov/pubmed/27329360 http://dx.doi.org/10.1007/s00280-016-3079-6

Ejemplares similares

Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation
por: Han, Kelong, et al.
Publicado: (2015)

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
por: Wang, Bei, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma
por: Kotani, Naoki, et al.
Publicado: (2022)

Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial
por: Han, Kelong, et al.
Publicado: (2014)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation
por: Han, Kelong, et al.
Publicado: (2016)

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(®)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
por: Quartino, Angelica L., et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
por: Yoshida, Kenta, et al.
Publicado: (2020)

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory
por: Schindler, Emilie, et al.
Publicado: (2018)

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model
por: Stillemans, Gabriel, et al.
Publicado: (2020)

Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
por: Chan, Phyllis, et al.
Publicado: (2020)

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
por: Quartino, Angelica L., et al.
Publicado: (2015)

Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function
por: Li, Anning, et al.
Publicado: (2023)

Pharmacokinetics of intravitreal bevacizumab (Avastin(®)) in rabbits
por: Sinapis, Christos I, et al.
Publicado: (2011)

Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome
por: Marier, Jean‐Francois, et al.
Publicado: (2021)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

External Evaluation of Population Pharmacokinetics Models of Lithium in the Bipolar Population
por: Aurélie, Lereclus, et al.
Publicado: (2023)

Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis
por: Marchand, Mathilde, et al.
Publicado: (2017)

External evaluation of published population pharmacokinetic models of posaconazole
por: Huang, Shuqi, et al.
Publicado: (2022)

Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation
por: Sanches, Cristina, et al.
Publicado: (2022)

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
por: Shemesh, Colby S., et al.
Publicado: (2019)

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
por: Quartino, Angelica L., et al.
Publicado: (2017)

Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X‐linked Hypophosphatemia
por: Lee, Sun Ku, et al.
Publicado: (2021)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2020)

Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long‐Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin
por: Lee, Sun Ku, et al.
Publicado: (2022)

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2019)

On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
por: Hård, Anna-Lena, et al.
Publicado: (2011)

Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes
por: Moisseiev, Elad, et al.
Publicado: (2013)

External Evaluation of Vancomycin Population Pharmacokinetic Models at Two Clinical Centers
por: Liu, Yi-Xi, et al.
Publicado: (2021)

External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab
por: Konecki, Celine, et al.
Publicado: (2021)

External Validation of a Pharmacokinetic Model of Propofol for Target-Controlled Infusion in Children under Two Years Old
por: Ji, Sang-Hwan, et al.
Publicado: (2020)

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
por: Li, Cheryl S. W., et al.
Publicado: (2019)

Validation of an obstetric comorbidity index in an external population
por: Metcalfe, A, et al.
Publicado: (2015)

Randomized Population Pharmacokinetic Analysis and Safety of Intravenous Acetaminophen for Acute Postoperative Pain in Neonates and Infants
por: Hammer, Gregory B., et al.
Publicado: (2019)

External Evaluation of Risperidone Population Pharmacokinetic Models Using Opportunistic Pediatric Data
por: Karatza, Eleni, et al.
Publicado: (2022)

Quantitative Property-Property Relationship for Screening-Level Prediction of Intrinsic Clearance of Volatile Organic Chemicals in Rats and Its Integration within PBPK Models to Predict Inhalation Pharmacokinetics in Humans
por: Peyret, Thomas, et al.
Publicado: (2012)

Integrated Two‐Analyte Population Pharmacokinetic Model for Antibody–Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling
por: Lu, D, et al.
Publicado: (2016)

1532. Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1-Infected Subjects
por: Han, Kelong, et al.
Publicado: (2019)

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
por: Liu, Stephanie N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_agimir31g4e73pqn4g1iiq04ph